entertainment -WSS

entertainment

author：comprehensive 2025-09-30 23:06:30 - browse：52

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Rise in cancer among younger people worries and puzzles doctors

WSS

Biden warns of ‘dark winter’ during final presidental debate

Biogen says it will cut costs by $700 million, slash 1,000 jobs

What it's like to live with paralysis for one psychologist

Truvian presents data for its desktop blood

What it's like to live with paralysis for one psychologist

The haunting brain science of long Covid

hotspot

entertainment

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

ChatGPT in medicine: STAT answers readers' burning questions

How to keep neuroscience’s past racism from being its future

After affirmative action ruling, medical educators look to 'holistic review'

Virtual care provider acquires bankrupt Pear's prescription apps

At least 13 dead in Texas as scorching temps continue

HCA sued by state AG for quality issues at Mission Health

Apple is now the first public company to be valued at $3 trillion

New Alzheimer's drugs heat up race for early detection blood tests

focus

What it's like to live with paralysis for one psychologist

Three trends to watch in biotech in 2024

Carvykti CAR

HCA sued by state AG for quality issues at Mission Health

Keeping primary care docs in field isn't impossible, says AAFP CEO

Grail spinoff by Illumina should end disastrous merger attempt

entertainment

focus

Wikipedia

hotspot